Valuation: Shanghai Rendu Biotechnology Co., Ltd.

Market Cap 1.72B 253M 221M 204M 188M 355M 24.37B 362M 2.44B 959M 11.93B 950M 929M 41.08B P/E 2024
-179x
P/E 2025 186x
Enterprise Value 901M 133M 116M 107M 98.77M 186M 12.8B 190M 1.28B 504M 6.27B 499M 488M 21.57B EV / Sales 2024
3.31x
EV / Sales 2025 6.55x
Free-Float
43.51%
Yield 2024
0.56%
Yield 2025 2.38%
05-14 Shanghai Rendu Biotechnology's share trade to resume from May 15 RE
05-14 Nanjing Haijing Pharmaceutical Co., Ltd. agreed to acquire 21.25% stake in Shanghai Rendu Biotechnology Co., Ltd. from Ju Jinliang, Qiming Weichuang Venture Capital Management Company Limited, Runcong Enterprise Management Center (Limited Partnership), China International Capital Corporation Limited, Qiming Ventures Fund III, Changzhou Jinxin Venture Capital Co., Ltd. and Novel Praise Limited for approximately CNY 520 million. CI
05-08 Rendu Biotech's Controlling Shareholder Eyes Share Transfer Deal MT
05-07 Trading in Shanghai Rendu Biotechnology's shares to halt RE
04-28 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
30/10/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/08/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
29/04/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/02/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
29/10/24 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
29/08/24 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 CI
20/08/24 Tranche Update on Shanghai Rendu Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 19, 2024. CI
1 day-7.16%
1 week-8.88%
Current month-20.02%
1 month-20.89%
3 months-13.92%
6 months-14.28%
Current year-8.56%
1 week 44
Extreme 44
48.93
1 month 44
Extreme 44
56.99
Current year 44
Extreme 44
63.56
1 year 43.28
Extreme 43.28
63.56
3 years 22.5
Extreme 22.5
63.56
5 years 22.5
Extreme 22.5
72
10 years 22.5
Extreme 22.5
72
Manager TitleAgeSince
Chief Executive Officer 43 09/12/2022
Chief Tech/Sci/R&D Officer 60 13/06/2007
Director of Finance/CFO 52 01/08/2015
Director TitleAgeSince
Chairman 60 13/06/2007
Director/Board Member 54 21/10/2020
Chairman 64 21/10/2020
Change 5-day change 1-year change 3-year change Capi.($)
-7.16%-8.88%-0.27%+0.36% 253M
+0.56%-2.61%+235.49%+311.48% 20.67B
+0.41%+4.58%-38.34%-21.74% 9.85B
+2.36%+1.85%+53.31%+18.55% 7B
-1.66%+2.36%+260.00%-25.12% 5.55B
+0.36%+3.63%-17.20%-24.16% 5.23B
+10.00%+34.69%+101.94%+130.90% 4.9B
+0.06%-2.94%-45.38% - 4.66B
-0.66%+0.73%-23.40%-26.29% 4.2B
-2.66%+4.71%-15.83%-39.64% 2.72B
Average +0.16%+4.59%+51.03%+36.04% 6.51B
Weighted average by Cap. +0.96%+3.63%+97.82%+107.82%

Financials

2024 2025
Net sales 177M 26.16M 22.87M 21.1M 19.45M 36.66M 2.52B 37.47M 252M 99.19M 1.23B 98.26M 96.11M 4.25B 162M 23.89M 20.88M 19.27M 17.76M 33.47M 2.3B 34.22M 230M 90.58M 1.13B 89.73M 87.76M 3.88B
Net income -7.81M -1.15M -1.01M -929K -857K -1.61M -111M -1.65M -11.11M -4.37M -54.36M -4.33M -4.23M -187M 10.09M 1.49M 1.3M 1.2M 1.11M 2.08M 143M 2.13M 14.34M 5.64M 70.19M 5.59M 5.47M 242M
Net Debt -798M -118M -103M -94.88M -87.46M -165M -11.33B -168M -1.13B -446M -5.55B -442M -432M -19.1B -815M -120M -105M -96.9M -89.32M -168M -11.57B -172M -1.16B -456M -5.67B -451M -441M -19.51B
Logo Shanghai Rendu Biotechnology Co., Ltd.
Shanghai Rendu Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production, and sales of molecular diagnostic reagents and equipment. The Company mainly operates three businesses. The reagent business is mainly engaged in the research, development, production, and sales of molecular diagnostic reagents for reproductive tract infections, respiratory tract infections, enteroviruses, and bloodborne infectious diseases, as well as other reagent products such as sample preservation solutions and nucleic acid extraction reagents. The instrument business is mainly engaged in the research, development, production, and sales of molecular diagnostic instruments such as the fully automated nucleic acid detection and analysis system (AutoSAT). The testing business is mainly engaged in the provision of clinical testing services, including pathogen detection for the genitourinary system, bloodborne pathogens, respiratory system, and digestive system.
Employees
239
Date Price Change Volume
17/07/26 CN¥44.23 -7.16% 459,735
16/07/26 CN¥47.64 -1.28% 276,966
15/07/26 CN¥48.26 +0.65% 343,662
14/07/26 CN¥47.95 +1.27% 312,908
13/07/26 CN¥47.35 -2.45% 387,057
  1. Stock Market
  2. Stocks
  3. 688193 Stock